Fair Value Calculator Fair Value Calculator
EN DE

MPAGI (MPAGI) Fair Value & Analysis

IN · Market cap ₹58.0M

M MPAGI MPAGI · BSE
Price₹9.99
Fair Value₹2.38
Upside-76.2%
Quality61/100
Watch MPAGI for free — get notified when fair value or trend changes. Watch for free
Evidence: Low Range ₹1.78 – ₹2.97

Fair value as of: Jul 5, 2026

From 6 valuation models · updated today

Share price −0.6% over the past month.

Price vs Fair Value (12 months)

₹12.41 ₹8.23 Fair Value ₹2.38 Jul 2025 Jul 2026

12‑month range ₹8.23 – ₹12.41 · fair‑value band ₹1.78 – ₹2.97 · the ₹9.99 price screens above the ₹2.38 fair value. As of Jul 5, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

MPAGI (MPAGI) currently trades at ₹9.99, while our model-based Fair Value estimate is ₹2.38 — implying the stock looks roughly 76.2% overvalued today. We read business quality at 61/100 (solid quality). Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

Over the trailing twelve months, MPAGI generated revenue of ₹4.0M at a net margin of 17.4%. It earns a return on equity of 1.2%. The stock trades on a trailing P/E of 83.3. Fundamentals as of Jul 5, 2026

Our scenario range runs from ₹1.78 (bear case) to ₹2.97 (bull case); at ₹9.99, the current price sits above that range. The share trades about 21% below its 52-week high and 21% above its 52-week low, currently below its 200-day average.

Key figures & financial health

Revenue (TTM) ₹4.0M
Net margin 17.4%
Return on equity 1.2%
Free cash flow −₹2.7M FY2026
P/E ratio 83.3
Operating margin -63.7%
More key figures
EPS (TTM) ₹0.1200
EPS growth (YoY) +313%

Figures from reported company fundamentals (EODHD) · as of Jul 5, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2022 – FY2026 · reported fiscal years

MPAGI reported revenue of ₹0 in FY2026 versus ₹0 in FY2022. Reported net income was ₹690K in FY2026, compounding +24.7%/yr from FY2022.

Revenue
FY22 ₹0
FY23 ₹0
FY24 ₹4.2M
FY25 ₹0
FY26 ₹0
Net income +24.7%/yr
FY22 ₹285K
FY23 ₹216K
FY24 ₹438K
FY25 ₹480K
FY26 ₹690K

Is MPAGI fairly valued? → Check now

🧮 Run the numbers yourself — free valuation calculators
📤 Share or link this analysis
🔗 Embed on your site (free fair-value badge)

Paste this into your site or blog — it shows the current fair value and links back here (free, and welcome):

Cite: Fair Value Calculator (2026). "MPAGI Fair Value". https://www.fairvalue-calculator.com/stock/MPAGI

Explore undervalued stocks

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap Stocks

Frequently asked questions

Is MPAGI (MPAGI) undervalued?
As of Jul 5, 2026, our model estimates a fair value of ₹2.38 versus a price of ₹9.99 — about −76% (overvalued). Model-based estimate, not financial advice.
What is the fair value of MPAGI?
Our model-based fair value for MPAGI is ₹2.38 (as of Jul 5, 2026), built from audited fundamentals. The current price is ₹9.99.
What is the quality score of MPAGI?
MPAGI has a Quality Score of 61/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.
What is the revenue of MPAGI (MPAGI)?
MPAGI reported trailing-twelve-month revenue of about ₹4.0M (latest available figure, as of Jul 5, 2026).
What is the net profit margin of MPAGI?
The net profit margin of MPAGI is about 17.4%, meaning it keeps roughly 17.4% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.